Company intelligence / Profile preview

MYOS CORP

Cedar Knolls, New Jersey, United Statesmyospet.com ↗

Ownership: Private
Employees: ~13
Development stage: Commercial

Overview

Fortetropin®, the core product of MYOS CORP, has been shown in eight successful clinical studies to increase muscle size and lean body mass while reducing atrophy. The company’s new line “MYOS MD” targets medical professionals for use cases such as age-related sarcopenia and recovery after surgery or weight loss treatments. Products are available commercially for both humans and animals.

Therapeutic areas: Metabolic DisordersEndocrinologyRare DiseasesOther
Modalities: Nutritional supplements based on bioactive compounds from fertilized egg yolk (Fortetropin®); not traditional small molecules or biologics
Industry: Food & Nutrition

Drug pipeline

1 asset

Fortetropin

Commercial

Indications: Muscle health, Post-surgical recovery, Muscle atrophy

Beyond the preview

Go deeper on MYOS CORP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYOS CORP.

Explore the full profile